Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

Bridgin Merron; Shamim Kazmi-Stokes; Thomas Cummin; Sharon Barrans; Shamzah Araf; Koorosh Korfi; Laura D Lopez Pascua; Josh Caddy; Kelly Cozens; Francesco Cucco; Rahman Uddin; Chulin Sha; Reuben Tooze; Gareth Griffiths; Ming Qing Du; Cathy Burton; David Westhead; Jude Fitzgibbon; Anna Schuh; Andrew Davies; Peter Johnson

首页> 外文期刊>Clinical medicine: journal of the Royal College of Physicians of London >Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

【24h】

Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

机译：淋巴瘤患者的精密药;嗜血性淋巴瘤（PMAL）联盟的嗜血精密药物

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

While conventional therapy is curative for most patients withhigh grade lymphomas, there is considerable heterogeneity inthis diagnosis, with scope to refine treatment according to theprecise molecular phenotype. This is increasingly used to guidespecific therapy and to predict outcomes. The Precision Medicinefor Aggressive Lymphomas (PMAL) consortium is a nationalmulti-partner network, established to develop robust predictivemolecular assays for patients with high grade lymphomas and tooptimise their treatment through trials of novel targeted therapybased on the results.

机译：虽然常规治疗是大多数有高级淋巴瘤的患者的疗效，但有相当大的异质性Inthis诊断，范围根据牙科的分子表型细化治疗。这越来越多地用于指导考试和预测结果。精确的药物攻击性淋巴瘤（PMAL）联盟是一个国家医疗合作伙伴网络，为高级淋巴瘤患者制定强大的预测性分子测定，并通过对结果进行的小说的试验进行治疗。

著录项

来源
《Clinical medicine: journal of the Royal College of Physicians of London》 |2019年第2期|共2页
作者
Bridgin Merron; Shamim Kazmi-Stokes; Thomas Cummin; Sharon Barrans; Shamzah Araf; Koorosh Korfi; Laura D Lopez Pascua; Josh Caddy; Kelly Cozens; Francesco Cucco; Rahman Uddin; Chulin Sha; Reuben Tooze; Gareth Griffiths; Ming Qing Du; Cathy Burton; David Westhead; Jude Fitzgibbon; Anna Schuh; Andrew Davies; Peter Johnson;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls [J] . DyerM.J.S., VoglerM., SamuelJ., British Journal of Haematology . 2013,第6期

机译：B细胞白血病和淋巴瘤的精密药物;进展和潜在的陷阱
2. The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use [J] . Elias P??an, Beatriz Flores, Ian Hudson, The oncologist . 2013,第5期

机译：欧洲药品管理局对匹克酮的治疗，用于治疗成年复发性或难治性侵袭性非霍奇金氏B细胞淋巴瘤成年患者：人类用药品委员会的科学评估摘要
3. Precision Medicines Need Precision Patient Assistance Programs [J] . A. Mark Fendrick, Jason D. Buxbaum The American journal of managed care . 2019,第7期

机译：精密药品需要精确患者援助计划
4. Cost-benefit analysis of patient's choice in precision medicine [C] . Yucheng Chen, Manuel Nunez Annual Conference of the Decision Sciences Institute . 2019

机译：患者选择精准医学的成本效益分析
5. Precision Medicine Approaches to Integrating Genomics with Cancer Therapy: Applications in Glioblastoma and Lymphoma [D] . Mooney, Marie R. 2016

机译：将基因组学与癌症治疗相结合的精密医学方法：在胶质母细胞瘤和淋巴瘤中的应用
6. Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium [O] . Bridgin Merron, Shamim Kazmi-Stokes, Thomas Cummin, 2019

机译：淋巴瘤患者的精准医学；侵袭性淋巴瘤（PMAL）联盟的血液精确医学
7. From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL) [O] . Michael T. Werner, Qian Zhang, Mariusz A. Wasik 2017

机译：从病理学到精确医学的间变性大细胞淋巴瘤表达间变性淋巴瘤激酶（aLK + aLCL）

Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

摘要

著录项

相似文献

相关主题

期刊订阅